Humoral and cellular response after varicella vaccination in VZV IgG seronegative kidney transplant candidates

Autor: Willem Weimar, Nicole M. van Besouw, Ronella de Kuiper, J.M. Zuijderwijk, Marieken J. Boer-Verschragen, Marcia M. L. Kho, Annemiek A. van der Eijk
Přispěvatelé: Internal Medicine, Virology
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Herpesvirus 3
Human
Varicella vaccine
viruses
T-Lymphocytes
Disease
medicine.disease_cause
Antibodies
Viral
0302 clinical medicine
030212 general & internal medicine
Prospective Studies
Kidney transplantation
Immunity
Cellular
integumentary system
virus diseases
Middle Aged
Vaccination
Infectious Diseases
Molecular Medicine
Female
Adult
Vaccines
Attenuated
End stage renal disease
Chickenpox Vaccine
03 medical and health sciences
Young Adult
SDG 3 - Good Health and Well-being
medicine
Humans
Adverse effect
Aged
General Veterinary
General Immunology and Microbiology
business.industry
Public Health
Environmental and Occupational Health
Varicella zoster virus
biochemical phenomena
metabolism
and nutrition
medicine.disease
Virology
Kidney Transplantation
eye diseases
Transplant Recipients
Immunity
Humoral
Transplantation
030104 developmental biology
Immunoglobulin G
Immunology
business
Immunologic Memory
Zdroj: Vaccine, 35(1), 71-76. Elsevier
ISSN: 1873-2518
0264-410X
Popis: Background In immunocompromised patients, primary infection with VZV may have a disastrous clinical course. Vaccination of VZV-seronegative patients on the waiting list for renal transplantation may prevent severe disease. However, the immunologic response of end-stage renal disease patients to peptide vaccines is far from optimal. Our question was whether end-stage renal disease patients with undetectable VZV-IgG levels were able to mount an adequate humoral and cellular response to a live attenuated varicella vaccine. Methods Kidney transplant candidates with undetectable VZV levels were vaccinated twice with a live attenuated varicella vaccine at an interval of 6 weeks. VZV IgG levels were analysed till 2 years after vaccination. The VZV-specific T-cell reactivity was determined prior to vaccination and after transplantation. Results Seventy-seven percent (40/52) of the vaccinees reached positive VZV-IgG levels after vaccination (responders). Eighty-two percent (9/11) showed an increase in VZV-specific CD4 + memory T-cells (both central and effector memory cells). The percentage VZV-specific CD8 + memory T-cells did not increase. None of the non-responders suffered from primary VZV after transplantation. No severe vaccine-related adverse events were reported, only spontaneously resolving local skin irritation. Conclusion The live attenuated varicella vaccine evokes positive VZV IgG-levels and VZV-specific memory T-cells in VZV-seronegative potential kidney transplant candidates.
Databáze: OpenAIRE
Externí odkaz: